Pediatric COVID-19 Therapeutics: Seizing the Right Research and Development Opportunities to Accelerate Access for Children
17 January 2022
Sebastien Morin, PhD; Marc Lallemant, MD; Anthony Garcia-Prats, MD; Linda Lewis, MD; Melynda Watkins, BSc Chem; Carlo Giaquinto, MD; Marie Valentin, PharmD; Martina Penazzato, PhD; and John C. Reeder, PhD; on behalf of the Global Accelerator for Paediatric Formulations (GAP-f).
Abstract: Children, although at lower risk of poor outcomes from COVID-19 relative to adults, still stand to benefit from therapeutic interventions. Understanding of COVID-19 clinical presentation and prognosis in children is essential to optimise therapeutic trials design. This perspective illustrates how to collectively accelerate paediatric COVID-19 therapeutic research and development, based on the experience of the Global Accelerator for Paediatric Formulations.